Careful choice of iodine contrast can spare sensitive kidneys

Article

Choosing an iso-osmolar dimeric contrast agent can reduce the risk of damage to kidneys in patients with diabetes or impaired renal function, according to a multinational study. Researchers in 17 centers evaluated serum creatinine output for 135

Choosing an iso-osmolar dimeric contrast agent can reduce the risk of damage to kidneys in patients with diabetes or impaired renal function, according to a multinational study.

Researchers in 17 centers evaluated serum creatinine output for 135 patients with impaired kidney function in a double-blinded study of iodixanol, an iso-osmolar nonionic dimeric contrast medium, and iohexol, a low-osmolar nonionic monomeric contrast medium.

Compared with a baseline reading, patients given iodixanol had an average peak increase of 11.2 mmol/L of creatinine during the next three days. For patients given iohexol, the increase was 48.2 mmol/L. Only 3% of patients given iodixanol crossed the threshold for nephrotoxicity, compared with 26.2% for iohexol patients.

The result, according to lead author Dr. Peter Aspelin of Huddinge University Hospital in Stockholm, was that patients given iodixanol were 11 times less likely to experience nephrotoxicity. The findings of the Nephrotoxicity in High Risk Patients study were published recently in the New England Journal of Medicine and presented at the European Congress of Radiology.

"The risk of nephropathy is already high in patients with diabetes mellitus," he said. "Iodixanol can lower that risk."

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.